Schizophrenia- Journey study
What is the purpose of this study?
The purpose of the Journey Study is to evaluate the effectiveness, safety, and tolerability of a study drug
in participants with schizophrenia who did not respond well enough to antipsychotic therapy and to find out how well the study drug works as an add-on therapy.
What study drug is being researched?
This study is evaluating the effectiveness of the study drug, valbenazine, compared to a placebo on symptoms of schizophrenia including hallucinations and confused thoughts. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients.
Who Can Participate?
You may Qualify if:
- Be age 13 or older and diagnosed with schizophrenia for at least 1 year prior to the start of the research study
- Have a history of not responding well to Antipsychotic treatment
- Be receiving antipsychotic therapy (not clozapine)
**There are additional eligibility requirements,
which the study doctor can explain to you**
Why should participants expect?
The total length of participation in the Journey Study is
up to 16 weeks, which includes 7 on-site study visits. This study comprises the following periods:
- Screening – This period lasts up to 4 weeks. During this period, the study team performs tests to make sure the study is a good match for the potential participant.
- Treatment period – This period lasts 10 weeks. During this period, participants will take their assigned study treatment of either the study drug or the placebo once daily.
- Follow-up period – This period lasts 2 weeks. During this period, participants will no longer take any study treatment. After 14 days from their last dose of the study treatment, participants will have a final on-site study visit, where the study team will ask questions and check the participant’s health.